Gelteq Limited - Ordinary Shares (GELS)
Gelteq Limited - Ordinary Shares (GELS) last closed at $0.55 (as of 2026-07-30). On Shishin's four-engine momentum model it scored 57/100, flagged by the Suzaku engine (Extended) on its most recent scan appearance (2026-06-16). It has surfaced in 1 daily scan since 2026-06-16. The figures below are research data, the Shishin Score and the momentum, trend, and volatility indicators the engines observe, not investment advice.
Price updates daily; the engine read reflects GELS's most recent scan appearance. Shishin's live daily signals are published each morning on the rankings board.
GELS did not make Shishin's board on 2026-07-31: below the liquidity floor (under about $20M traded/day). This is a mechanical screen result, not a view on the company.
What is GELS's Shishin momentum score?
As of 2026-06-16, GELS scores 57/100 on Shishin's four-engine composite, flagged by the Suzaku engine. The score blends momentum, trend, and volatility indicators on a 0 to 100 scale.
Is GELS showing a momentum setup?
GELS's current setup state is "Extended." This describes what the engines observe in the chart structure, it is a data classification, not a recommendation to buy or sell.
Which Shishin engine flags GELS?
Most recently the Suzaku engine. Each of the four guardians is tuned for a different market regime.
How often has GELS appeared in Shishin scans?
GELS has appeared in 1 daily scan since 2026-06-16. Recurring appearances indicate a persistent setup; one-off appearances are more transient.
How is the Shishin Score calculated?
The Shishin Score (0 to 100) is a weighted blend of momentum (multi-horizon returns), trend (moving-average stack, distance from MAs), and volatility/liquidity (ADR, ATR, dollar volume) indicators, scored per the engine active for the current market regime.
Research data, not investment advice. Shishin publishes what its systematic engines observe; it does not recommend buying or selling any security, and is not a registered investment adviser or broker-dealer. See our risk disclosure.